Followers | 31 |
Posts | 2649 |
Boards Moderated | 0 |
Alias Born | 10/28/2013 |
Monday, July 28, 2014 12:12:16 AM
But I can't follow all the details, nor am I an MD. Not sure if the doctors did much wrong. His main complaint makes sense regarding the patient confidence, but it is not likely to have been a big factor in her longevity.
It would be so difficult, as an Oncologist, to carry that level of responsibility all the time.
I just hope that drug selection is not influenced by marketing and kickbacks, etc.. If so... and it results in people dying or dying sooner, then that is a big deal. Not saying that went on hear, at all. But this reminded me how upset I am about that issue.
You hear it said regularly... ie.. "At least CLDX and NW are not trying to buck SOC with their GBM treatments." That this somehow greatly increases their odds of approval. If that's true, and it is widely accepted to be true, then somebody should hang.
DCVax-L needs Temador. I saw the test results presented by Dr. Lau. It is not about trying to make Merck or the FDA happy. But if keeping SOC increases the odds of a product getting approved, separate and apart from performance, then something is very wrong. And that is the accepted state of the state.
I hope Direct proves out. It seems like a perfect answer to Breast cancer, in part because the guided injections would be so easy in a breast.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM